[Integrative medicine : what's new in 2024].

This article reports on new findings on integrative and complementary medicine published in 2024. The implementation of guidelines for the management of pain in cancer patients is discussed. Then, a literature review is presented, that aims to clarify the role of complementary approaches in the management of chemotherapy-induced nausea and vomiting and provides a concrete example of how recommendations are established.

Trends in EMS encounters and outcomes among children and adolescents with firearm injuries from 2018 to 2022.

Objective: To describe changes in patient and encounter characteristics among Emergency Medical Services (EMS) responses for patients ages 0-19 with firearm-related injuries.

Methods: This retrospective national analysis used data from the 2018-2022 ESO Data Collaborative and included all 9-1-1 records for patients ages 0-19 years with documentation of firearm-related injuries. Percent changes are reported; annual changes were evaluated using a non-parametric test of trend.

Michigan tobacco cessation champions: A rapid qualitative analysis.

Background: Smoking is the leading cause of preventable death in the United States. We interviewed Tobacco Cessation Champions, multi-sector decision makers, across the state of Michigan to assess and identify barriers and facilitators of smoking cessation and the current smoking cessation landscape.

Methods: Twenty Tobacco Cessation Champion interviews ( = 20) were completed with multi-sector decision makers to assess implementation barriers and facilitators from May 2022 to September 2023.

The Double-Edged Sword of Third-Party Resources: Examining Use and Financial Burden of Extracurricular Tools in Medical Students.

Background: According to the Association of American Medical Colleges (AAMC) Year 2 questionnaire, the percentage of students using online medical education videos (Boards and Beyond®Sketchy Medical®, Youtube) at least once per week increased from 47.7% (2015) to 70.1% (2022).

Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.

Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.